These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7607739

  • 1. Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs.
    McMahon EG, Yang PC, Babler MA, Bittner SE, Suleymanov OD, Cain-Janicki KJ, Bedell LJ, Hanson GJ, Cook CS.
    Hypertension; 1995 Jul; 26(1):95-100. PubMed ID: 7607739
    [Abstract] [Full Text] [Related]

  • 2. Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.
    Ryan MJ, Hicks GW, Batley BL, Rapundalo ST, Patt WC, Taylor DG, Keiser JA.
    J Pharmacol Exp Ther; 1994 Jan; 268(1):372-9. PubMed ID: 8301578
    [Abstract] [Full Text] [Related]

  • 3. A comparsion of the effects of prazosin and hydrallazine on blood pressure, heart rate and plasma renin activity in conscious renal hypertensive dogs.
    Massingham R, Hayden ML.
    Eur J Pharmacol; 1975 Jan; 30(1):121-4. PubMed ID: 1122933
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of SC-52458, an angiotensin AT1 receptor antagonist, in the dog.
    McMahon EG, Yang PC, Babler MA, Suleymanov OD, Palomo MA, Olins GM, Cook CS.
    Am J Hypertens; 1997 Jun; 10(6):671-7. PubMed ID: 9194514
    [Abstract] [Full Text] [Related]

  • 6. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs.
    Wessale JL, Kleinert HD, Calzadilla SV, Kovar PJ, Rosenberg SH.
    Am J Hypertens; 1993 Jun; 6(6 Pt 1):514-21. PubMed ID: 8343235
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A novel renal hypertensive guinea pig model for comparing different inhibitors of the renin-angiotensin system.
    Duan J, Jaramillo J, Jung GL, McLeod AL, Fernandes BH.
    J Pharmacol Toxicol Methods; 1996 Apr; 35(2):83-9. PubMed ID: 8729434
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
    Laubie M, Schiavi P, Vincent M, Schmitt H.
    J Cardiovasc Pharmacol; 1984 Apr; 6(6):1076-82. PubMed ID: 6084763
    [Abstract] [Full Text] [Related]

  • 11. Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs.
    Shibasaki M, Fujimori A, Kusayama T, Tokioka T, Satoh Y, Okazaki T, Uchida W, Inagaki O, Yanagisawa I.
    Eur J Pharmacol; 1997 Sep 24; 335(2-3):175-84. PubMed ID: 9369371
    [Abstract] [Full Text] [Related]

  • 12. Renin--angiotensin antagonists and the regulation of blood pressure.
    Samuels AI, Miller ED, Fray JC, Haber E, Barger AC.
    Fed Proc; 1976 Nov 24; 35(13):2512-20. PubMed ID: 185095
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J, Wuerzner G, Jensen C, Brunner HR.
    Hypertension; 2002 Jan 24; 39(1):E1-8. PubMed ID: 11799102
    [Abstract] [Full Text] [Related]

  • 14. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects.
    Ménard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD.
    Circulation; 1995 Jan 15; 91(2):330-8. PubMed ID: 7805235
    [Abstract] [Full Text] [Related]

  • 15. KRI-1314: an orally effective inhibitor of human renin.
    Etoh Y, Miyazaki M, Saitoh H, Toda N.
    Jpn J Pharmacol; 1993 Sep 15; 63(1):109-19. PubMed ID: 8271523
    [Abstract] [Full Text] [Related]

  • 16. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273.
    Kleinert HD, Stein HH, Boyd S, Fung AK, Baker WR, Verburg KM, Polakowski JS, Kovar P, Barlow J, Cohen J.
    Hypertension; 1992 Dec 15; 20(6):768-75. PubMed ID: 1452292
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive activity of captopril (SQ 14,225), an orally active inhibitor of angiotensin converting enzyme in conscious two-kidney perinephritic hypertensive dogs.
    Vollmer RR, Boccagno JA, Steinbacher TE, Horovitz ZP, Murthy VS.
    J Pharmacol Exp Ther; 1981 Feb 15; 216(2):225-31. PubMed ID: 6257882
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist.
    Wong YN, Wong PC.
    J Pharm Pharmacol; 1996 May 15; 48(5):492-7. PubMed ID: 8799873
    [Abstract] [Full Text] [Related]

  • 19. Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist.
    Olins GM, Corpus VM, Chen ST, McMahon EG, Palomo MA, McGraw DE, Smits GJ, Null CL, Brown MA, Bittner SE.
    J Cardiovasc Pharmacol; 1993 Oct 15; 22(4):617-25. PubMed ID: 7505365
    [Abstract] [Full Text] [Related]

  • 20. Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.
    Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, Mertz TE, Olszewski BJ, Randolph AE, Singer RM, Kaplan HR.
    J Pharmacol Exp Ther; 1984 Feb 15; 228(2):312-8. PubMed ID: 6319675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.